Charcot-Marie-Tooth Disease Type 1 - 24 Studies Found
Not yet recruiting |
: Tools for Therapeutic Evaluation in Charcot-Marie-Tooth Disease Type 1A: Outcome Measures and Biomarkers : Charcot-Marie-Tooth Disease Type 1A : 2015-10-30 :
|
Not yet recruiting |
: Correlation Between Clinical and Electrophysiological Phenotypes in a Population of Patients With Neuropathy Charcot-Marie-Tooth Disease Type 1A : Charcot-Marie-Tooth Type 1A Neuropathy : 2012-11-16 |
Active, not recruiting |
: Phase III Trial Assessing the Efficacy and Safety of PXT3003 in CMT1A Patients (PLEO-CMT) : Charcot-Marie-Tooth Disease Type 1A : 2015-09-28 :
|
Active, not recruiting |
: Treadmill, Stretching and Proprioceptive Exercise (TreSPE) Rehabilitation Program for Charcot−Marie−Tooth Neuropathy Type 1A (CMT1A) :
|
Recruiting |
: Assessing Long Term Safety and Tolerability of PXT3003 in Patients With Charcot-Marie-Tooth Disease Type 1A : Charcot-Marie-Tooth Disease, Type IA : 2016-12-26 : Drug: PXT3003 Liquid oral solution, 5 mL bid for 9 consecutive months |
Completed |
: Phase II, Randomized, Placebo-controlled Trial in Patients With Charcot-marie-tooth Disease Type 1A :
: |
Recruiting |
: Study of ACE-083 in Patients With Charcot-Marie-Tooth Disease : Charcot-Marie-Tooth Disease : 2017-04-12 : Drug: ACE-083 Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solutio |
Completed |
: High Dose Ascorbic Acid Treatment of CMT1A : Charcot-Marie-Tooth Disease, Type Ia : 2007-06-08 :
|
Completed |
: Ascorbic Acid Treatment in CMT1A Trial (AATIC) :
: 2006-01-03 :
|
Recruiting |
: SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study :
|